In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...
Read MoreIn a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib in older patients with chronic lymphocytic leukemia. This study concluded that ibrutinib is safe and effective in these patients. Some background Ibrutinib (Imbruvica) is a targeted therapy for chronic lymphocytic leukemia (CLL). Targeted therapies block...
Read More
In a nutshell This study evaluated the impact of radiotherapy on the outcomes of rituximab (Rituxan)-treated patients with primary breast diffuse large B-cell lymphoma. This study concluded that radiotherapy has significant therapeutic benefits for these patients. Some background Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare type of...
Read More
Methods and Findings The study looked at female patients with metastatic TNBC. They had not had any previous treatment. Three different combinations of chemotherapy were assessed. Nab-paclitaxel + carboplatin (PC), gemcitabine + carboplatin (GC), and nab-paclitaxel + gemcitabine (PG). 191 patients were randomly assigned one of the three...
Read MoreIn a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...
Read More
In a nutshell This study aimed to investigate the accuracy of positron emission tomography/computed tomography (PET/CT) scanning and bone marrow biopsy (BMB) to assess bone marrow involvement (BMI) in children with newly diagnosed Hodgkin lymphoma. The main finding was that PET/CT was effective in determining BMI and biopsy should only be...
Read MoreIn a nutshell The study looked at the impact of other medical conditions (comorbidities) on the effectiveness of ibrutinib (Imbruvica) in the treatment of chronic lymphocytic leukemia (CLL). The study concluded that having a number of other conditions was associated with a poorer prognosis in CLL patients treated with ibrutinib. Some background...
Read MoreIn a nutshell This study examined whether 6 or 8 cycles of R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy led to better survival outcomes in patients with newly diagnosed diffuse large B-cell lymphoma. This study concluded that outcomes following 6 or 8 cycles of R-CHOP-21 are similar for these patients. Some...
Read MoreIn a nutshell This study looked at the risk of infection in older patients with indolent non-Hodgkin lymphoma (nHL) treated with bendamustine (Treanda). Researchers concluded that nHL patients treated with bendamustine had increased risk of common bacterial, fungal, and viral infections. Some background Bendamustine is a chemotherapy drug sometimes...
Read MoreIn a nutshell This study aimed to investigate the effectiveness of venetoclax in chronic lymphocytic leukemia patients with 17p deletion. This study concluded that venetoclax is effective in this group of patients. Some background 17p deletion chronic lymphocytic leukemia (17p del CLL) is a type of CLL that has a poor prognosis.Venetoclax...
Read MoreIn a nutshell This study aimed to investigate the effectiveness of venetoclax in chronic lymphocytic leukemia patients with 17p deletion. This study concluded that venetoclax is effective in this group of patients. Some background 17p deletion chronic lymphocytic leukemia (17p del CLL) is a type of CLL that has a poor prognosis.Venetoclax...
Read MoreIn a nutshell This study examined the risk of venous thromboembolism (VTE, a blood clot that forms in the veins of the legs, arms, or groin) in patients treated with lenalidomide (Revlimid). The study concluded that the risk of VTE was low with lenalidomide treatment. Some background Lenalidomide is an effective treatment already used in multiple...
Read More
